secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001140361-24-046728
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics reports Q3 net loss of $11.2M; NAVIGATE trial top-line results expected Dec 2024
--------------------------------------------------------------------------------

- Net loss $11.2M ($0.18/share) vs $14.0M ($0.24) in Q3 2023; R&D expense $7.6M, G&A $1.5M.
- Cash $27.1M at Sept 30, 2024; $6M credit line from chairman; runway through May 2025.
- NAVIGATE trial of belapectin in MASH cirrhosis top-line efficacy/safety results expected December 2024.
- Three belapectin abstracts accepted for poster presentation at AASLD 2024 annual meeting.
- Annual stockholder meeting set for January 23, 2025 due to NAVIGATE trial timing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124046728/0001140361-24-046728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124046728/ef20038321_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-046728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer